Clinical Trial Update: 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of tanespimycin (17-AAG) for metastatic malignant melanoma has completed. Sponsor: Cancer Research UK.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Tanespimycin (17-AAG) (tanespimycin)

Snippet

Sponsor: Cancer Research UK | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED